Daiichi Life Insurance Co. Ltd. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Geri Gentry on Aug 24th, 2026

Daiichi Life Insurance Co. Ltd. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 4,579 shares of the biopharmaceutical company’s stock, valued at approximately $2,855,000.

A number of other large investors have also recently bought and sold shares of REGN. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth $26,000. Titan Wealth CI Ltd bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $29,000. Finally, Trust Co. of Vermont bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $29,000. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,400 shares of company stock valued at $1,090,030. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $834.04 on Monday. The firm has a market capitalization of $85.87 billion, a price-to-earnings ratio of 20.61, a price-to-earnings-growth ratio of 1.42 and a beta of 0.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $847.00. The stock’s fifty day moving average is $697.09 and its 200-day moving average is $716.46.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $12.81 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on REGN shares. Citigroup upped their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. HSBC cut their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Canaccord Genuity Group dropped their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $801.70.

Get Our Latest Analysis on REGN

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.